JP7758320B2 - 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 - Google Patents

5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法

Info

Publication number
JP7758320B2
JP7758320B2 JP2020541352A JP2020541352A JP7758320B2 JP 7758320 B2 JP7758320 B2 JP 7758320B2 JP 2020541352 A JP2020541352 A JP 2020541352A JP 2020541352 A JP2020541352 A JP 2020541352A JP 7758320 B2 JP7758320 B2 JP 7758320B2
Authority
JP
Japan
Prior art keywords
htp
carbidopa
low
dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020541352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511365A (ja
JP2021511365A5 (cg-RX-API-DMAC7.html
Inventor
ジェイコブセン,ジェイコブ・ピー・アール
キャロン,マーク・ジー
Original Assignee
デューク・ユニヴァーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デューク・ユニヴァーシティ filed Critical デューク・ユニヴァーシティ
Publication of JP2021511365A publication Critical patent/JP2021511365A/ja
Publication of JP2021511365A5 publication Critical patent/JP2021511365A5/ja
Priority to JP2023119314A priority Critical patent/JP2023153871A/ja
Application granted granted Critical
Publication of JP7758320B2 publication Critical patent/JP7758320B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020541352A 2018-01-29 2019-01-28 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法 Active JP7758320B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023119314A JP2023153871A (ja) 2018-01-29 2023-07-21 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862623073P 2018-01-29 2018-01-29
US62/623,073 2018-01-29
US201862743816P 2018-10-10 2018-10-10
US62/743,816 2018-10-10
PCT/US2019/015391 WO2019148087A1 (en) 2018-01-29 2019-01-28 Compositions and methods of enhancing 5-hydroxytryptophan bioavailability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023119314A Division JP2023153871A (ja) 2018-01-29 2023-07-21 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法

Publications (3)

Publication Number Publication Date
JP2021511365A JP2021511365A (ja) 2021-05-06
JP2021511365A5 JP2021511365A5 (cg-RX-API-DMAC7.html) 2022-01-25
JP7758320B2 true JP7758320B2 (ja) 2025-10-22

Family

ID=67395723

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541352A Active JP7758320B2 (ja) 2018-01-29 2019-01-28 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
JP2023119314A Withdrawn JP2023153871A (ja) 2018-01-29 2023-07-21 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023119314A Withdrawn JP2023153871A (ja) 2018-01-29 2023-07-21 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法

Country Status (14)

Country Link
US (1) US11337963B2 (cg-RX-API-DMAC7.html)
EP (1) EP3746058B1 (cg-RX-API-DMAC7.html)
JP (2) JP7758320B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250025043A (cg-RX-API-DMAC7.html)
CN (1) CN111902137A (cg-RX-API-DMAC7.html)
AU (1) AU2019211458B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015068A2 (cg-RX-API-DMAC7.html)
ES (1) ES2948788T3 (cg-RX-API-DMAC7.html)
IL (1) IL276059B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020007760A (cg-RX-API-DMAC7.html)
MY (1) MY209656A (cg-RX-API-DMAC7.html)
RU (1) RU2020125170A (cg-RX-API-DMAC7.html)
SG (1) SG11202007178VA (cg-RX-API-DMAC7.html)
WO (1) WO2019148087A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409163B2 (en) * 2021-07-30 2025-09-09 Evecxia Therapeutics, Inc. Method of enhancing 5-hydroxytryptophan (5-HTP) exposure
AU2022320730A1 (en) 2021-07-30 2024-03-14 Evecxia Therapeutics, Inc. 5-hydroxytryptophan gastroretentive dosage forms
US11779567B2 (en) 2021-10-14 2023-10-10 Evecxia Therapeutics, Inc. Method for optimizing 5-hydroxytryptamine function in the brain for therapeutic purposes
DE102022103658A1 (de) * 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer
WO2024148354A1 (en) 2023-01-06 2024-07-11 Evecxia Therapeutics, Inc. A method of enhancing 5-hydroxytryptophan (5-htp) exposure
CN119074695B (zh) * 2024-08-29 2026-07-24 江南大学 一种可提高脑内5-ht水平的口服缓释制剂及其在改善失眠中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130230577A1 (en) 2010-10-22 2013-09-05 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658038A (en) 1982-10-07 1987-04-14 Research Foundation For Mental Hygiene, Inc. N-acylated 5-hydroxytryptophan amide derivatives
FR2654931B1 (fr) 1989-11-24 1993-08-27 Trouillas Paul Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa.
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
US6207699B1 (en) * 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20060013875A1 (en) 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
EP1751312A4 (en) 2004-05-21 2010-01-27 Univ Duke POLYMORPHISM IN TRYPTOPHAN HYDROXYLASE 2 REGULATING BRAIN SEROTONIN SYNTHESIS
US20070213370A1 (en) 2005-11-18 2007-09-13 H. Lundbeck A/S 5-HTP Combination Therapy
US8969400B2 (en) 2007-10-01 2015-03-03 Duke University Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
ES2740360T3 (es) 2008-08-15 2020-02-05 Assertio Therapeutics Inc Composiciones farmacéuticas de retención gástrica para el tratamiento y la prevención de trastornos del SNC
CA2788675C (en) * 2010-02-05 2018-01-16 Phosphagenics Limited Carrier composition
CN103554005A (zh) 2013-11-22 2014-02-05 长沙理工大学 一种左旋5-羟基色氨酸的简便合成新方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130230577A1 (en) 2010-10-22 2013-09-05 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies

Also Published As

Publication number Publication date
JP2021511365A (ja) 2021-05-06
EP3746058A1 (en) 2020-12-09
IL276059B1 (en) 2024-04-01
KR20250025043A (ko) 2025-02-20
BR112020015068A2 (pt) 2021-01-05
EP3746058C0 (en) 2023-06-07
JP2023153871A (ja) 2023-10-18
US20210346345A1 (en) 2021-11-11
EP3746058A4 (en) 2021-12-22
US11337963B2 (en) 2022-05-24
KR20200116110A (ko) 2020-10-08
EP3746058B1 (en) 2023-06-07
SG11202007178VA (en) 2020-08-28
IL276059B2 (en) 2024-08-01
CN111902137A (zh) 2020-11-06
ES2948788T3 (es) 2023-09-19
MY209656A (en) 2025-07-29
WO2019148087A1 (en) 2019-08-01
AU2019211458B2 (en) 2024-08-29
IL276059A (en) 2020-08-31
AU2019211458A1 (en) 2020-08-06
CA3089068A1 (en) 2019-08-01
MX2020007760A (es) 2020-10-28
RU2020125170A (ru) 2022-02-28

Similar Documents

Publication Publication Date Title
JP2023153871A (ja) 5-ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
CA2548917C (en) Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
RS20050851A (sr) Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
MX2008014840A (es) Tratamiento de trastornos depresivos.
US20090264522A1 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
NZ543586A (en) Gaboxadol4,5,6,7-tetrahydroisoxazolo-[5,4-c]pyridine-3-ol or THIP in monotherapy for treating depression and other affective disorders
AU2006265009A1 (en) Combinations of eszopiclone and an antidepressant
EA014576B1 (ru) Комбинированные препараты, содержащие бифепрунокс и l-допу
US20100303903A1 (en) Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
US20100292248A1 (en) Combination preparations comprising slv308 and a dopamine agonist
AU2018371628B2 (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
CA3089068C (en) Low-dose carbidopa for enhancing 5-hydroxytryptophan bioavailability
WO2007144421A1 (en) Combination preparations comprising slv308 and a l-dopa
WO2025125884A1 (en) Mirtazapine and venlafaxine compositions with antidepressant effects and which do not alter sexual behavior
JP2007511577A (ja) (2s,3s)−2−(3−クロロフェニル)−3,5,5−トリメチル−2−モルホリノールの使用
MX2008016226A (es) Preparaciones de combinacion que comprenden bifeprunox y l-dopa.
MX2008016225A (es) Preparaciones de combinacion que comprenden slv308 y l-dopa.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251002

R150 Certificate of patent or registration of utility model

Ref document number: 7758320

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150